Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma vs. Standard Plasma for COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
There are 2 groups of research subjects: plasma donor and recipients~Volunteer plasma donors can donate Convalescent Plasma if they:~* have adequate antibody levels against COVID-19 per FDA Guidelines~* have had no symptoms of COVID-19 for at least 14 days~* meet routine plasma donation criteria~Inclusion Criteria for Plasma Recipients:~* Adults 18 years of age or older~* Hospitalized with PCR+ COVID-19 infection~* If female must not be pregnant and/or breastfeeding.~Exclusion Criteria for Plasma Recipients:~* Unable to randomize patient within 14 days of admission to Stony Brook Hospital (or any other hospital if a transfer to Stony Brook Hospital).~* In the treating physician's opinion, the patient cannot tolerate a 450-550 mL infusion of plasma over up to 8 hours (4 hours max per unit), even if prophylaxed with intravenous diuretic~* Contraindication to transfusion or history of prior reactions to blood transfusions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent Donor Plasma (Type: ACTIVE_COMPARATOR): None
- Standard Donor Plasma (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).